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ABSTRACT

SERUM IgG CONCENTRATIONS OF NEONATAL CALVES FED COLOSTRUM
REPLACER SUPPLEMENTED WITH LACTOFERRIN

by
Erin C. Shea
University o f New Hampshire, May 2007

The objective o f this experiment was to determine the effect o f various levels of
lactoferrin supplementation in colostrum replacer fed as 1 or 2 doses on apparent
efficiency o f IgG absorption, serum IgG concentrations, and intestinal development in
neonatal Holstein bull calves. Eighty-Holstein bull calves were assigned to a 2 x 4
factorial arrangement o f treatments in a completely randomized block design. Bull calves
were collected at two locations, Fairchild Teaching and Research Center at the University
o f New Hampshire (n = 48) and a commercial dairy (n = 32). All calves were fed
colostrum replacer (CR) according to manufacturer’s recommendations within 90 min of
birth with or without lactoferrin treatment. Lactoferrin treatments were 0 (control), 0.5,
1, and 2 g/d. At 12 h o f age calves were fed either a second feeding o f CR with or
without Lf or 2 L o f milk replacer (MR) with or without Lf. Calves continued to be fed
MR with or without L f in 12 h increments throughout the duration o f study. Calves from
the commercial dairy were removed from study at 48 h, while calves bom at the
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university were removed from the study at 72 h. Blood samples were collected for IgG at
0, 6, 12, 18, 24, and 48 h. On average, all calves attained blood serum IgG concentration
> 10 mg/mL resulting in successful passive transfer, except for calves fed 1 dose o f CR 1
or 2 g/d of supplemental Lf. However, there was an effect on CR feeding with calves fed
2 doses o f CR having significantly higher blood serum IgG concentrations. There was no
effect o f L f supplementation on plasma IgG and serum protein. There was a decrease in
apparent efficiency o f absorption (AEA) of IgG when 2 doses o f CR were fed versus 1
dose of CR. Lactoferrin supplementation resulted in a suppressing quadratic effect on
AEA of IgG. At the sixth feeding in which calves were 60 + 2 h o f age, D-xylose
(0.5g/kg BW) was mixed with the MR with or without supplemental L f (UNH calves) to
determine xylose absorption by the small intestine. Blood samples were collected before
xylose was fed at 0, and 2, 4, 6, 8, and 12 h after feeding xylose, for measurement of
plasma glucose and xylose concentrations. Xylose means and area under the curved
showed L f to have a quadratic effect on xylose absorption with 0.5 and 1 g/d of
supplemental L f having lower plasma xylose concentrations then calves fed 0 and 2 g/d
of supplemental Lf. There was no effect of CR feeding or supplemental Lf on plasma
glucose concentrations. This study indicates supplementing Lf to a CR has a negative
effect on both serum IgG and xylose absorption, demonstrating supplemental L f is not
beneficial to the neonatal calf.

xiii
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CHAPTER I
REVIEW OF LITERATURE

Part 1: Nutritional and Immunological needs of the Neonatal Calf
Introduction
The first step in successful heifer management begins with the first colostrum
feeding. High quality maternal colostrum is designed to meet the nutritional and
immunological needs o f the neonatal calf. If high quality colostrum is not fed to the calf
at birth, the calf will have a higher chance for morbidity and mortality. The three largest
costs during the first three months o f age are feed, labor, and medication (Quigley,
1996b). These costs are reduced if the calf receives high quality colostrum in the first 24
h o f life. This is due to successful passive transfer o f IgG, resulting in blood serum IgG
concentrations >10mg/mL. Failure o f passive transfer (<10mg/mL) will not only result
in economic loss during the first 3 months but throughout the animals entire life. Calf
weights at 60, 120, and 180 d have been positively correlated with serum
immunoglobulins obtained by successful passive transfer (Odde, 1986). There is also a
correlation between failure o f passive transfer and a negative impact o f future milk
production and an increase in mortality among dairy cows (Porto et al., 2007).
These findings have led to research related to colostrum management and factors
affecting IgG absorption. Products such as colostrum replacers and supplements have
been developed that will either provide both nutritional and immunological needs of the
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calf or aid in increasing the quality of maternal colostrum. Although these products may
be beneficial when high quality colostrum is unavailable, they do not consistently
provide. Successful passive transfer (Foster, 2006). In order for improvement of these
products to occur, there needs to be a better understanding of other components found in
maternal colostrum and their role in intestinal development and IgG absorption. Part 1 of
this review provides an understanding o f why the neonatal calf has certain nutritional and
immunological needs and how these needs can be met. Part 2 o f this review will focus on
the bioactive protein lactoferrin, and how its biological functions may be beneficial to the
neonatal calf.
Placental Transfer
Placentas are classified for their morphological and structural differences. The
bovine placenta is morphologically classified as a cotyledonary placenta, due to the
cotyledons, which attach the placenta to the uterine wall (Senger, 1999). The placenta is
structurally classified as a synepitheliachorial placenta because it consists of three
maternal and three fetal membranes (Senger, 1999). It is through these morphological
and structural characteristics that determine what substances are allowed to pass through
the placenta from dam to fetus.
The dam and fetus have completely separate blood supplies resulting in no direct
blood flow from one to the other (Blowey, 1999). The cotyledons, which attach the
placenta to the uterine wall, are the site o f nutrient and waste transfer between the dam
and fetus. At this location, blood vessels grow very close together allowing for an
exchange o f nutrients from dam to fetus and waste from fetus to dam (Blowey, 1999).
However, only small molecules are allowed to pass between the dam and fetal blood
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vessels (Blowey, 1999). This prevents large molecules such as Ig from reaching the
fetus, resulting in the calf being bom hypogammaglobulinemic.
The placenta also regulates the exchange o f other nutrients such as glucose and
amino acids. Glucose and amino acids are transported across the placenta by facilitated
diffusion using specific carrier molecules (Senger, 1999). Lipids are not able to cross
through the placenta, which also prevents fat soluble vitamins (A, D, E) from passing to
the fetus. This results in the neonatal calf having high nutritional needs at birth.
Characteristics of Neonatal Calf
Immunological and nutritional needs. The metabolic adjustments necessary in the
transition from a fetus to a neonatal calf are dramatic. The neonatal calf has very high
nutritional needs due to the selective transfer o f molecules through the placenta. The
neonatal calf needs immunity, energy, protein, vitamins and minerals for it to survive. At
birth, the calf has only 3 % body fat, which is critical for development, and therefore, not
available as an energy source (Akers, 2002). It is estimated that the total fat and
glycogen available to the calf at birth would be used up in about 18 h without
supplemental feeding (Davis and Drackley, 1998). The limited amount o f glycogen
stored in the liver or other tissues is rapidly used, and gluconeogenesis is limited in the
liver at this time. M other Nature has compensated for the lack o f Ig and nutrients passed
through the placenta by having the first secretion from the mammary gland, known as
colostrum, being an excellent source o f both immunological protection and nutrients
needed for survival.
Characteristics of the gastrointestinal tract. Another important aspect concerning
the neonatal calf is that the rumen is nonfunctional. At birth, the abomasum accounts for
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about 70% o f the volume o f the entire stomach. The rumen, reticulum, and omasum
account for the other 30%. This is dramatically different from the mature animal where
the forestomach (rumen, reticulum, and omasum) accounts for more than 90% and the
abomasum less then 10% of the stomach (Church, 1988). This makes a neonatal c a lf s
digestive system similar to simple stomach animals such as the pig and human.
Milk bypasses the rumen and flows directly into the abomasum through the
formation o f the esophageal groove. The esophageal groove is formed through the
muscular folds o f the reticulum (Church, 1988). Neural stimulation from suckling and
milk proteins results in the formation of the groove, extending the esophagus to the
abomasum. Due to the specific proteins found in milk, colostrum, and milk replacer the
esophageal groove will form whether calves drink from a bottle or bucket. However,
water alone will not cause the groove to form resulting in water entering the rumen
(Church, 1988).
Immunity Overview
The immune system is composed o f two defense mechanisms, cell-mediated
immunity and humoral immunity. Cell-mediated immunity involves T lymphocytes (T
cells) which protect the body against cells that have been infected by viruses, parasites, or
even cancer cells (Akers, 2002). Humoral immunity is comprised o f B lymphocytes (Bcells) that can differentiate into plasma cells, which secrete antibodies. Antibodies also
known as immunoglobulins are antigen-binding glycoproteins present on the B-cell
membrane and secreted by plasma cells (Goldsby, 2003). The roles o f antibodies are to
bind to bacteria and their toxins or to bind to free viruses, making them inactive (Akers,
2002). The antibody-antigen complex results in the antigen being susceptible to
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destruction by phagocytes or complement activation (Akers, 2002). There are five major
classes o f Ig: IgA, IgG, IgM, IgD, and IgE, all o f which have a specific function within
the immune system. The prevalence o f a certain class o f Ig depends on the species of
animal. Ruminants have nearly all their Ig as IgG, while humans have more than 80% of
their Ig as IgA (Akers, 2002).
The humoral immune system is comprised of memory B cells, which are
responsible for the increase in antibody concentration when an animal is exposed to the
same pathogen a second time. The memory B cells have the ability to recognize a
pathogen in which the body has already been exposed, thus allowing for a faster immune
response that will destroy the pathogen, preventing the animal from becoming ill.
At birth the c a lf s immune system is immature, resulting in its inability to make Ig
and fight the pathogens it becomes exposed to at birth. The calf receives the Ig required
to fight disease through the cow’s colostrum it ingests. The cow has already been
exposed to pathogens on the farm resulting in her immune system having specific Ig that
can recognize and destroy this harmful pathogen. When the calf consumes the colostrum
it is also ingesting these pre-made Ig, resulting in the calf having the Ig required to fight
the pathogens it is exposed to and increasing its chances of survival.
Immunoglobulin Structure and Function
Each antibody molecule is comprised of two identical heavy chains and two
identical light chains, which are linked together by disulfide bonds (Akers, 2002). The
shape o f the antibody molecule resembles the letter Y with the two heavy chains making
up both the arms and stem. The light chains overlap portions o f the heavy chains in the
arms, and are joined to the heavy chains by a disulfide bond and by noncovalent
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interactions such as salt linkages, hydrogen bonds, and hydrophobic bonds to form a
heterodimer (Goldsby, 2003). The two identical heavy chains forming the stem of the Y
are also linked together by noncovalent interactions and disulfide bonds (Goldsby, 2003).
The two arms are classified as the Fab portion and the stem is considered the Fc domain
(Rojas and Apodaca, 2002). The sites for binding o f the antibody to the antigen are found
at the two top ends o f the Fab portion. These sites are known as the V regions (variable
region) due to their highly variable sequence of 110 or so amino acids. The sequence of
these amino acids determines the Ig specificity to an antigen (Goldsby, 2003). One Ig
molecule is capable o f binding at least two antigen molecules making the Ig divalent
(Akers, 2002). The Fc domain interacts with molecules such as complement or Fc
receptors, marking the antibody-antigen complex for destruction by, either neutralization,
precipitation, agglutination, or opsonization (Akers, 2002).

Structure of an IgG Molecule

Ch ’
P ap ain

SS

—ss

H inge

CHO
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Immunoglobulin G. IgG has a molecular weight o f 180,000 (Anderson et al.,
1985) and is the most abundant class of antibodies found in blood serum and lymph. In
all animals, IgG works to fight against bacteria, fungi, viruses, and foreign particles. It is
the smallest Ig, which allows it to leave the blood stream and enter body pools were it can
fight antigens. Immunoglobulin G is divided into subclasses IgGl and IgG2, with IgGl
being the most prevalent in the bovine serum. The structural characteristics that
distinguish these subclasses from one another are the size o f the hinge region and the
number and position o f the interchain disulfide bonds between the heavy chains
(Goldsby, 2003).
Immunoglobulin M. IgM is the class o f antibodies found in circulating body
fluids. It has a molecular weight o f 900,000 and is expressed as a membrane bound
antibody on B cells (Anderson, 1985; Goldsby 2003). It is comprised o f five monomer
units held together by disulfide bonds, resulting in its pentamer shape. This
distinguishing characteristic allows IgM to be much more efficient then IgG when
neutralizing a viral infection or activating the complement system. Immunoglobulin M
can bind 10 small molecules or 5 larger molecules where IgG can only bind two at the
most (Goldsby, 2003). Immunoglobulin M is the first antibody to appear in response to
an initial exposure to an antigen (Goldsby, 2003). Due to the large size o f IgM, it does
not diffuse well and therefore found in very low concentrations in the intracellular tissue
fluids; however, it does play an important accessory role to IgA as a secretory molecule
(Goldsby 2003).

Structure of IgM molecule
7
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Immunoglobulin A. Immunoglobulin A has a molecular weight o f 380,000
(Anderson et al, 1985) and is an antibody whose main function is to fight ingested
antigens. It is found in mucosal and exocrine gland secretions (Rojas and Apodaca,
2002). The highest level o f IgA secreted is by the intestine due to the constant interaction
with endogenous flora and external microbes (Didierlaurent et al, 2002). To compensate
for the lack o f a fully functional immune system in the neonatal calf colostrum contains
IgA, which coats the intestinal lining, preventing pathogens from attaching and causing
disease. Immunoglobulin A binds antigens such as bacteria, viruses, parasites, and
toxins. This Ig works by preventing the attachment and invasion o f external pathogens
into the mucosal surface by hindering their motility. For example, IgA can inhibit
flagella function, induce microbial aggregation, compete with pathogens for adhesion
sites, and to neutralize viruses (Williams and Gibbons, 1972). Immunoglobulin A and
antigen complexes are entrapped in mucus and then eliminated by the ciliated epithelial
cell of the respiratory tract or by peristalsis o f the gut (Goldsby, 2003).

Structure o f IgA molecule
Colostrum
Colostrum is the first secretion from the mammary gland after calving and is
designed to meet the nutritional needs o f the neonatal calf. Bovine colostrum is
composed o f 14% protein, 6.7% fat, and 2.7% lactose, while milk, which is classified as
about the sixth milking or the third day after calving, has 3.1% protein, 3.5% fat, and 5%
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lactose (Akers, 2003). As for Ig, bovine colostrum is composed o f 75% IgG, 12% IgM,
and 12% IgA while bovine milk contains only about 0.6% IgG and even lower levels of
IgM and IgA (Foley and Otterby, 1978). Colostrum supplies the newborn with its first
line of defense, nutrients, and growth factors.
Colostrogenesis. Colostrum is formed through the process known as
colostrogenesis. Colostrogenesis is a process during late gestation, which results in the
transfer o f serum IgG into the mammary gland (Holland, 1990). Blood IgG enters lacteal
secretions by a specific intracellular transport mechanism (Anderson et al., 1985).
Immunoglobulin G is divided into two subclasses, IgG l and IgG2. Immunoglobulin G1
is the most prevalent immunoglobulin found in bovine colostrum. It occurs in
concentrations 5-20 times that o f IgG2 due to the high prevalence o f IgG l specific
receptors on the secretory cells (Anderson et al., 1985). IgGl is transported from the
serum to the colostrum, by first diffusing across the vascular epithelium and then
selectively transported by mammary epithelial cells (Butler, 1983). Immunoglobulin G
then specifically binds via Fc-specific receptors located on the basal membrane of the
secretory epithelium (Butler, 1983). The basal membrane then engulfs the IgG molecule,
which will then be released into the colostrum (Holland, 1990). The onset o f lactogenesis
rapidly decreases IgG transport, suggesting that the hormones responsible for alveolar
cell differentiation may also suppress colostrogenesis (Akers, 2003). During the transfer
of IgG from the serum to the colostrum, there is a significant decrease in maternal serum
IgG and constant increase in colostrum IgG (Butler, 1983).
Immunoglobulin M and IgA are less prevalent in bovine colostrum and rather
then coming directly from the maternal blood serum they are synthesized in the
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mammary gland. They are synthesized in plasma cells lying adjacent to the secretory
epithelium (Anderson et al., 1985). Following synthesis IgA binds to a protein receptor
known as the secretory component, forming a complex called secretory IgA (slgA),
which consist o f two IgA molecules, the J chain, and the secretory component (Anderson
et al., 1985). Secretory IgA then moves through the secretory cell to the apical surface
and is discharged into the colostrum (Anderson et al., 1985). The pathway o f IgM is
believed to be similar to IgA.
Colostrum Quality. The quality of colostrum is classified according to its IgG
concentration; low quality < 22 mg o f IgG/mL, medium quality 22 to 50 mg of IgG/mL,
and high quality > 50 mg o f IgG/mL. The IgG concentration is often measured indirectly
using a colostrometer. The colostrometer measures the specific gravity o f the colostrum,
which equates to the Ig level. The higher the specific gravity the higher the colostrum
quality.
The quality varies between breeds and the parity o f the cow. Jerseys have higher
quality colostrum because they produce colostrum that has a higher percentage o f solids
then a Holstein cow (Akers, 2003). In addition, cows that produce less milk normally
have higher IgG concentrations due to the milk being more concentrated. A multiparous
cow has higher quality colostrum, because it has been exposed to more pathogens and
thus has built up a stronger immune system then a primiparous cow. If the calf is fed
higher quality colostrum, they will have the amount o f IgG required to fight disease...
Colostral Nutrients
Protein. Colostrum is composed of 14% protein. Proteins are synthesized from
amino acids derived either from the blood stream or from amino acids synthesized by the

10

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

secretory cells (Akers, 2002). Consumption of large amounts of amino acids is critical
for the stimulation o f protein metabolism in the neonatal calf (Quigley and Drewry,
1998). The neonate begins protein synthesis in the visceral organs, brain, lungs, and
skeletal muscle, within a few hours after birth (Quigley and Drewry, 1998).
The primary milk protein casein, coagulates in the abomasum forming a clot of
milk. Casein is then slowly digested, providing a source o f amino acids between meals
(Quigley and Drewry, 1998). Other proteins such as P-lactoglobulin and a- lactalbumin
are simply degraded in the abomasum and quickly hydrolyzed into amino acids (Quigley
and Drewry, 1998). The large mass of Ig in colostrum provides an important source of
amino acids even though they are more slowly digested (Quigley and Drewry, 1998).
The neonate will establish homeostasis once enough amino acids are available for protein
synthesis and gluconeogenesis (Quigley and Drewry, 1998).
Other proteins such as lactoferrin (Lf) and transferrin have a bioactive role in the
nonspecific defense to a bacterial infection. They have the ability to inhibit growth of
Gram-positive and Gram-negative bacteria because o f their ability to sequester iron and
limit its use by the bacteria (Akers, 2002). Properties o f L f will be discussed further in
part 2.
Energy. The high fat content o f colostrum (6.7% ) is important to the neonate
immediately after birth. The neonatal calf only has 3% body fat resulting in the neonate
having poor insulation (Akers, 2002). The total fat and glycogen available to the calf at
birth would be used up in about 18 h without supplemental feeding (Davis and Drackly,
1998). The colostral energy content may affect the thermoregulation and fatty acid
oxidation that are necessary to sustain gluconeogenesis (Quigley and Drewry, 1998). The
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faster the calf reaches homeostasis the higher its chances for survival (Santoro, 2001).
Heat production was increased by 18 and 9% in the first and second hour after colostrum
consumption in calves maintained in a 10°C environment (Vermorel et al., 1983)
Vitamins and Minerals. Fat soluble vitamins A, D, and E do not cross the
placental barrier, resulting in colostrum being the primary source o f these nutrients for
the calf after birth (Quigley and Drewry, 1998). Supplementation o f Vitamin A and E (atocopherol) to the dry cow diet is important to have adequate amounts o f these nutrients
in colostrum (Quigley and Drewry, 1998). Vitamins A and E are not present in the
calves’ blood stream at birth, while Vitamin D may be synthesized by precursors in the
c a lf s tissue (Santoro et al., 2004). Nemec et al. (1994) showed that Vitamin E improved
the development o f cellular immunity in neonatal pigs. Vitamin A plays a role in
maintaining a healthy epithelium, growth, bone formation, immune function, and protein
synthesis (Rufibach et al., 2006; Franklin et al., 1998; De Luca et al., 1969).
Selenium crosses the placenta and may accumulate in fetal tissues, such as the
liver. Dietary selenium (120mg o f Se/kg) has been reported to increase colostral IgG and
it absorption by the neonatal calf (Swecker et al., 1995). Colostrum is also more
concentrated then milk in zinc, iron, folic acid, choline, and riboflavin (Akers, 2002).
Passive Transfer
The transfer o f IgG from mother to neonatal calf through colostrum is known as
passive transfer. This provides the neonate with a form of passive immunization, which
is the acquisition o f immunity by a receipt o f preformed Ig rather than by active
production o f Ig after exposure to antigens (Goldsby, 2003). The absorption o f IgG
across the small intestine appears to be species specific. In a number o f newborn animal
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species, selectivity has evolved to the exclusion of the transport o f nearly all proteins,
such as man, guinea pig, and rabbit, whereas in others, such as the pig and the ruminant
selectivity appears to be poorly developed. There is also an intermediate group of
selectivity, which includes the rat, mouse, and perhaps carnivores (Staley and Bush,
1985).
In the small intestine of neonatal mice and rats, the FcRn receptor is expressed at
high levels by intestinal epithelial cells and mediates absorption o f IgG by receptormediated transcytosis (Mayer et al., 2002). FcRn is a major histocompatibility complex
class 1- related protein that mediates bidirectional IgG transcytosis in a variety o f tissues
(Rojas and Apodaca, 2002). Receptors are adapted to fit their attachment sites onto the
Fc-portion o f Ig (Staley and Bush, 1985). It appears the binding o f IgG to the FcRn
receptors is pFI-dependent (Jones and Waldman, 1972; Rodewald, 1976), occurring at a
pH o f 6.0 to 6.5, which is similar the pH of the luminal content o f the small intestine
(Staley and Bush, 1985). The FcRn expression is developmentally down-regulated,
resulting in almost complete loss o f intestinal FcRn at the time o f weaning in mice
(Mayer et al., 2002).
The mechanisim o f IgG absorption across the small intestine o f ruminants is less
complex. Previous studies have shown the possibility of the absorptive epithelieal cells
within the jejunum o f the neonatal calf possessing receptors, such as mice and rats, which
mediate the binding and cellular transport of Ig (Butler, 1983; Widdowson, 1985). Staley
and Bush (1985) introduced IgG conjugated to ferritin, and ferritin suspended in boiled
bovine colostral whey into the jejunum and observed the jejunal cells did not take up the
ferritin, but ferritin conjugated to IgG was observed in the apical tubular complex. The
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conjugated ferritin was not transported into the vacuolar system o f the cell and did not
exit the cell. Cells in the ileum, however were the most active in the uptake of ferritinIgG or ferritin. This study indicates the calves may have some selectivity in absorption,
based on the particular protein rather then molecular weight in the jejunum. However,
selectivity was not shown in the ileum in which both ferritin-IgG or ferritin were found
(Staley and Bush, 1985).
It appears in more recent studies that absorption o f IgG in ruminants occurs nonselectively during the first 24 h o f life by pinocytosis (Mayer et al., 2002). Pinocytosis is
a type o f endocytosis in which a cell ingests extracellular fluid and the material dissolved
in it (Goldsby, 2003). Mayer et al. (2002) were not able to detect FcRn in enterocytes,
which are the cells responsible for the initial absorption o f intestinal IgG. This would
support other studies that found Ig uptake to be a non-specific event. However, FcRn was
expressed by the crypt cells o f the newborn lamb, which may be responsible for IgGl
being the major Ig in the secretions o f the small intestine (Mayer et al., 2002). This
indicates that FcRn is responsible for IgG being brought back into the mucosa from the
neonate’s blood stream to fight infection along with IgA. No matter how IgG is absorbed
across the small intestine, the passive humoral immunity supplied to the neonate at this
time is essential for its survival.
Successful passive transfer is considered to be achieved when the serum IgG
concentration is equal to or greater then lOg/L at 24 h after birth. The national dairy
heifer evaluation project found that 40% of all calves sampled between 24 and 48 h had
an IgG concentration o f < lOg/L and over 25% < 6.2g/L (Wells et al., 1996). The
economic impact o f failure o f passive transfer (< 1Og/L o f IgG) at 24 h after birth is
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substantial. Management procedures and products that improve passive immunity in
calves are crucial to the dairy industry.
Gut Closure. Gut closure is the necessary phenomenon that allows for the
maturation o f the digestive system, resulting in the cessation o f absorption of
macromolecules from the small intestine by about 24 h after birth (Stott et al., 1979).
The maturation process o f the small intestine includes multiple events, such as intestinal
cell turnover, increasing abomasum acidity, development o f intestinal secretions, and
appearance o f intra-epithelial digestive vacuoles.
Factors Effecting Passive Transfer
Time o f First Feeding. Many factors affect whether or not the calf will receive
successful passive transfer. Age of the calf at first colostrum feeding has a large impact
on IgG absorption. An experiment by Haines et al. (1993) showed that serum IgG
declined from over 14g/L when fed at birth to less then lOg/L when feed 6 h after birth.
Only calves fed colostrum before 6 h had serum IgG levels greater then lOg/L. This is
due to the maturation o f the intestinal tract, resulting in the loss o f absorptive sites in the
small intestine. At birth there is also a limited amount o f enzyme secretions, allowing
IgG to pass to the small intestine where it can be absorbed as a whole molecule. By 12 h
after birth enzyme secretions become more active, decreasing the chance o f the IgG
molecule to reach circulation. Quigley et al. (1995) showed that serum IgG and IgM
concentration could be increased by adding lg o f soybean trypsin inhibitor to colostrum.
The soybean trypsin inhibitor reduced the activity o f trypsin in the small intestine
allowing more o f the Ig molecules to be absorbed.
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Delaying the first colostrum feeding also enhances the risk o f bacterial
colonization o f the intestine. Bacteria can compete with IgG molecules for absorption
sites, thus decreasing the amount o f IgG absorbed. The ingestion o f bacteria also may
accelerate the gut closure process. Logen et al. (1977) challenged calves with Escherichia
coli either before or after the first colostrum feeding. Seventy-five percent o f the calves
receiving E.coli before colostrum feeding died while none of the calves that received
colostrum first died.
Quantity and Apparent Efficiency o f Absorption. In addition to the timing of
colostrum ingestion, serum IgG concentration depends on the mass o f IgG consumed
(Kruse, 1970; Stott et al., 1979; Stott and Fellah, 1983). The mass o f IgG consumed
depends on the volume o f colostrum fed, IgG concentration of the colostrum, and the
efficiency o f absorption of IgG by the calf (Morin et al., 1997).
The apparent efficiency o f absorption (AEA) is equal to
[Plasma IgG at 24 h (g/L) x BW(kg)x0.092]/IgG intake(g)], with 0.092 representing the
average blood volume (9.2% o f BW) (Quigley et al., 1998). Research data suggest that
the average AEA o f IgG from maternal colostrum is about 35% (Quigley and Drewry,
1998). This data indicates that an average newborn weighing 40 kg must consume at
least 103 g of IgG by 24 h to achieve a blood serum concentration o f lOg/L (Quigley et
al., 2002). In order to consume at least 103 g o f IgG, the calf must ingest a minimum of
2.1 L o f high quality colostrum (50g/L) within 2 hours after birth, for successful passive
transfer to occur.
Levieux and Oilier (1999) estimated that 18% of dairy cows produce colostrum
yielding less then the required amount o f 100 g o f IgG, for successful passive transfer.
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Do to this variability in colostrum quality and variability in calf birth weight, it is
recommended that the calf receive 4 L o f high quality colostrum within the first 12 h of
life. The main practice on dairy farms involves feeding 2 L at birth and another 2 L at 12
h later. If a total o f 4 L o f high quality colostrum (>50mg/ml o f IgG) is fed either in one
feeding or split into two feedings then the calf should receive the desired amount o f 103g
of IgG within the first 12 hours o f life (Kruse, 1970).
Method of Feeding. The method o f feeding colostrum also has an effect the c a lf s
ability to receive passive transfer. There are three management practices used on the
dairy farm to administer the first colostrum feeding. The first method is to allow the calf
to nurse from the dam. However, having the calf nurse from the dam increases its risk of
failure o f passive transfer. The calf may have difficulty finding the udder and ingest
bedding and feces, which may contain harmful bacteria. In addition, when nursing from
the dam one cannot determine the amount, o f colostrum consumed. Without consuming
sufficient quantities o f colostrum, the calf will not be able to obtain the required amount
o f IgG to prevent failure of passive transfer. The last concern when allowing the calf to
nurse from the dam is the delay o f standing which results in a delay o f consumption.
The other methods o f feeding are through the use of a bottle or an esophageal
feeder. They both allow the farmer to control o f the time and quantity in which the calf
consumes the colostrum. However, studies show a slight increase in IgG absorption in
calves feed by a bottle rather then the esophageal feeder. This is due to the different path
colostrum takes though the gastrointestinal tract when an esophageal feeder is used.
When a calf nurses from either the dam or the bottle, the suckling reflex and milk
proteins cause the formation o f the esophageal groove. The formation o f the esophageal
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groove results in the milk by passing the rumen and flowing directly into the abomasum.
In the method of using an esophageal feeder the esophageal groove does not form,
resulting in the colostrum being deposited into the nonfunctional rumen. It then takes the
milk two to four hours to leave the rumen, which may result in lower AEA due to the
decrease in absorption sites over time.
Disease risk associated with colostrum feeding
Johne’s Disease. Johne’s Disease is a contagious disease o f the intestinal tract
caused by the bacteria Mycobacterium Paratuberculosis. The ileum becomes thick due to
an inflammatory response caused by the infection. This prevents the intestine from
functioning normally. The animal will continue to eat normally but will be unable to
absorb nutrients resulting in the animal becoming anorexic and eventually dying.
Johne’s has an incubation time of 2 to 5 years, in which time the animal may not
be showing signs o f the disease but still shedding the bacteria. Johne’s is age dependent,
meaning it takes a smaller dose to infect a calf then it would to infect an adult cow. This
results in calves less than 6 months o f age being the most susceptible. The bacterium is
spread through manure, milk, and colostrum. The probability o f calves becoming
infected by drinking milk from infected cows is a direct function o f time spent with the
cow. If the calf remains with the cow for an extended period o f time, she will have
nursed more often thus having more exposure to the bacteria, either through ingestion of
the colostrum or o f manure on teats.
It is estimated that >22% o f United States dairies are infected with Johne’s
disease and that it costs the producers $245 per cow/yr and the United States’ dairy
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industry $200-250 million annually (NAHMS, 2002). The high costs are due to a 2-19%
reduction in milk yield, increased cull rate, and greater mortality.
Bovine Leukosis Virus. Bovine Leukosis Virus (BLV) is a virus that survives in
the lymphocytes and once the animal is infected, it is infected for life. NAHMS (2002)
reported that 89% o f United States dairy operations have cattle infected seropositive for
BLV. The virus survives in the lymphocytes, which are found in blood, milk, and
colostrum along with other body fluids. If the calf ingests the BLV containing colostrum
or milk, it will become infected. There is also a 4-8% chance o f BLV crossing the
placenta and infecting the fetus. However, only 5% o f the cows infected with the virus
ever develop the clinical diseases because it does not show up until later in life. In
addition, it may remain dormant until brought on by stress.
Bovine Leukosis Virus causes a reduction in milk production and reproductive
performance. The reduced performance is caused by tumors, which may develop in the
abomasum resulting in loss o f appetite, and tumors developing on the uterus. The largest
economic impact o f BLV is the number of carcasses condemned at slaughter plants. The
number of condemned carcasses at slaughter has tripled since 1975. This is based on the
number o f lymph node tumors, indicating that a stronger elimination program needs to be
established. In addition, purebred breeders suffer the biggest economic losses, because
buyers do not want to bring the virus into their herd. The vims can also be spread
through the semen, so many major artificial insemination companies will only accept
semen from bulls that test negative.
There are other diseases such as BVD and salmonella that can be transferred to
the calf through the ingestion of colostrum. Both can be detrimental to the c a lf s health
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and increase their chances o f morbidity and mortality. Management procedures need to
be implemented on dairies, which minimize the spread o f disease through colostrum
feeding. This will then result in an overall healthier and more productive herd.
Colostrum replacer and supplements
The recognition o f high rates o f failure o f passive transfer (FPT) in calves and the
risk of transferring disease to calves has lead to areas of research which would provide
additional IgG or an alternative source o f maternal colostrum. Dairy producers now have
the option o f feeding a colostrum replacer or colostrum supplement when high quality
maternal colostrum is not available. Colostrum replacements may also be used as a part
o f biosecurity programs to prevent transmission o f disease-causing organisms such as
Salmonella spp, Mycobacterium paratuberculosis, bovine leukemia virus, and bovine
viral diarrhea virus (Foster et al., 2006). Colostrum replacer is defined as having > 100 g
IgG/dose and providing other nutrients required by the calf (Quigley et al., 2002b). A
colostrum supplement has < lOOg IgG/dose and is not formulated to replace maternal
colostrum but rather be fed with it (Quigley et al., 2002b). Supplements do not provide
the necessary energy, amino acids, or vitamins and minerals necessary for the c a lf s
development. Colostrum replacers and supplements were introduced into the market in
the mid to late 1980’s and have become an important class of products for producers.
Annually more then 500,000 calves in the U.S. are treated with colostrum products as a
means o f improving success of passive transfer and reducing cost associated with
neonatal disease. Three sources o f IgG that may be used in formulating colostrum
supplements and replacers are lacteal secretions (colostrum and milk), blood, and eggs.
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Lacteal Secretions. Colostrum supplements or replacers from lacteal secretions
are derived from dried colostrum or whey secretions. Though these products maybe
convenient and have been shown to protect calves under some circumstances, the Ig
content is highly variable. Colostrum supplements have been found to range from 0.3
grams to 17.8 grams o f IgG per dose, resulting in the calf being at a risk o f FPT if only
fed a colostrum supplement (Haines et al., 1990; Hunt and Hunt, 1991). The production
o f an effective replacer for bovine colostrum is dependent upon processing only
colostrum containing high Ig concentrations and upon having an efficient method of
dehydration, which preserves Ig function (Chelack et al. 1993). In a study conducted by
Chelack et al. (1993), only colostrum collected from the first two postpartum milkings of
multiparous cows contained sufficient immunoglobulin mass to be suitable for processing
into a colostrum replacer. Chelack et al. (1993) also tested three dehydration methods of
colostrum; freeze-dried, microwave vacuum evaporation, and spray-dried colostrum.
Freeze-drying was found to be the most effective method for maintenance o f Ig function
and recovery o f total solids. However, the lengthy processing time, high energy
consumption, severely limited processing capacity, and high maintenance costs resulted
in freeze-drying o f large volumes o f colostrum not being economical. The spray-drying
method was the fastest and most energy efficient, costing 2.5 times less than either
freeze-drying or microwave vacuum evaporation (Chelack et al, 1993). Spay-drying
involves having atomized droplets o f colostrum contact a countercurrent o f hot air,
resulting in heat transfer which promotes dehydration (Chelack et al. 1993). The spraydried colostrum retained 94% o f the Ig mass with minimal loss of Ig function; however,
there was a 25% loss in total solids (Chelack et al, 1993). The end result was a product
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that provided 126 g o f IgG when fed to calves. The serum IgG at 48 h o f age was 11.6
and 10.6 g/L for calves fed the colostrum and spay-dried colostrum, respectively.
However, even with these developments of processing colostrum products that contain
the required amount o f lOOg o f IgG/ dose, no milk- or colostrum-based replacer products
have been shown to routinely result in serum IgG concentrations > lOg/L (Foster et al.,
2006).
Mee et al. (1996) conducted a study in which a whey protein concentrate (W PC)
was fed as a colostrum substitute and compared to maternal colostrum. Calves fed the
WPC alone had a 24 hour serum IgG concentration o f only 3.0 mg/mL compared to
calves fed maternal colostrum which had a serum IgG concentration o f 17.8mg/mL. This
resulted in calves fed the WPC having a higher mortality rate (P < 0.05). The WPC was
derived from ultrafiltrated and freeze-dried cheese whey collected from thousands o f cow
in North America. This processing method alone would result in high variability in IgG
and nutrients within the product itself. Other studies have compared commercially
available colostrum-based replacement products and evaluated their effect on serum IgG.
These studies (Foster et al., 2006; Garry et al., 1996) found a high variability in
colostrum replacement products alone, with some colostrum based products providing
sufficient IgG for passive transfer while other products did not, even if all products
provided the required amount o f >100g of IgG/dose. It is estimated that the AEA of
colostrum replacer based on lacteal secretions ranges form 5 to 30% (Mee et al., 1996;
Arthington et al., 2000). The variability of AEA among products and within the product
itself results in the high variability o f whether a calf will receive passive transfer when
fed a lacteal secretion based colostrum replacer. In addition, with maternal colostrum
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having an AEA o f 35% would also explain why calves fed maternal colostrum have a
higher percentage rate o f successful passive transfer. The reason for the lower AEA in
colostrum products is yet to be fully understood.
Bovine Serum Extracts. Colostrum replacer/supplements derived from serum
protein generally have an AEA of 25-30%, which is higher then lacteal secretion based
products and similar to maternal colostrum (Arthington et al., 2000; Quigley et al., 1998).
It is also the least expensive source since bovine blood is plentiful and considered a waste
product from slaughter houses. It has high levels of IgG with little IgM and IgA.
Bovine blood is collected from sources that are under USD A inspection and
approved for human consumption. Bovine serum powder can be prepared by removing
fibrin by addition o f excess Ca, and the resulting serum is concentrated by filtration and
spray-dried to produce a light tan powder (Quigley et al., 2001). The bovine serum
powder is then mixed with other ingredients so it will provide the calf with both its
immunological and nutritional needs.
Quigley at al. (2001) demonstrated that the method used for fractionation of
bovine plasma to manufacture CR influenced absorption o f IgG. The results of this study
showed that when polyethylene glycol was used in the fractionation process, plasma IgG
concentrations in the calf were reduced. This may have been caused by altered
absorption kinetics, equilibration o f IgG with nonvascular IgG pools or metabolism of
IgG by the body within the first 24 h Quigley at al. (2001). Polyethylene glycol is used
widely as a method for purifying IgG from plasma, lacteal secretions, and eggs (Akita
and Nakai, 1993; Svendsen et al., 1995; Uemura et al., 1989) and may be the result of
lower AEA in colostrum products compared to maternal colostrum.
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Although, bovine serum based colostrum products are the most effective in
assuring successful passive transfer when compared to other products, it is no longer
allowed in countries where the use o f animal proteins has been banned. This is due to the
concern of diseases such as BSE being transferred from animals to humans during
consumption.
Chicken Egg. Hens are hyperimmunized to produce IgY, which is the chicken
form of IgG. The resulting eggs have high titers against the target antigen (Ikemori et al.,
1997). The eggs are concentrated and sprayed-dried. Egg IgY is used as a source of oral
Ig, which only provides local protection in the small intestine. The IgY is not well
absorbed across the small intestines (Kuroki et a.., 1993; Ikemori et al., 1997; HennigPauka et al., 2003).
Limitations to colostrum products: There are many limitations to the use of
colostrum supplements and replacers. For example, the profile o f antibody specificity in
a colostrum product may vary markedly from the antigenic reservoir on a dairy farm.
Although the calf may absorb significant IgG, they may provide little protection if they
are specific for the wrong pathogens. Biosecurity is also another potential risk when
feeding an animal protein from an unknown source. Colostrum products may be exposed
to such things as pasteurization and irradiation for the purpose o f eliminating pathogens,
however the risk o f transmission o f disease is not completely ameliorated. Another
negative aspect o f colostrum products is that the processing steps such as pasteurization
and spray-drying will reduce the activity o f important colostral components such as
colostral lymphocytes and heat labile proteins. Lastly, the cost o f feeding a colostrum
supplement or replacer is expensive.

24

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Part 2; Lactoferrin
Introduction
Lactoferrin is an iron binding glycoprotein o f the transferrin family. It is widely
distributed in the physiological fluids o f mammals (Saito et al., 1991). Unlike transferrin,
which can be found in species as distant as insects, L f can only be found in mammals,
suggesting that its emergence had to do with infant nutrition and protection (Baker and
Baker, 2005). Lactoferrin is believed to have evolved through the duplication of the
transferrin gene at the time o f emergence of mammals, with subsequent divergence in its
amino acid sequence and functional properties (Baker and Baker, 2005). It can be found
in fluids such as tears (Kiljistra et al., 1983), bronchial mucus (Fahy, 1993), secondary
granules (PMN’s), (Bennett and Kokocinski, 1978), cerebrospinal fluid (Talukder, 2003),
and milk (Molenaar et al.,1996).
Lactoferrin was first discovered in the whey fraction o f cow ’s milk (Sorensen and
Sorensen, 1939). Its most striking characteristic was its intense red color when incubated
in the presence o f Fe3+ ions (Baker and Baker, 2005). The site o f L f synthesis is assumed
to be the epithelia from which it is secreted (Sanchez et al., 1992).
The concentration of L f in milk varies between species and the stage of lactation.
Humans have the highest concentration at 4 mg o f Lf/ mL of milk, while rats and rabbits
have no L f (Sanchez, 1992), and in the cow, goat, and sow milk, the L f concentration is
between (20-200ug/mL) (Cowles et al, 2005). The concentrations o f this protein have
also been well documented for cows during colostrogenesis, lactation, and involution
(Smith and Schanbacher, 1977). Lactoferrin is elevated in colostrum (1 to 2 mg/mL) but
is low during lactation (0.01 to lmg/mL); L f increases to between 20 and lOOmg/mL in
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the secretion that is produced during involution (Molenaar et al., 1996). There are also
breed and parity effects, with dairy breeds having higher concentrations o f L f than beef
breeds and multiparous cows having higher amounts than primiparous cows (Tsuji et al.,
1990). The health of the mammary gland also plays a role in the amount o f Lf found in
the milk. As the somatic cell count increases, so does the level o f L f (Harmon et al.,
1977). It is believed that the L f produced in the mammary gland may play a role in both
protecting the mammary gland of the cow and the intestinal tract o f the newborn from
infection.
Lactoferrin plays a role in the innate immune system, which works as the first
line of defense against infection. It has many biological functions such as antibacterial
activity (Law and Reiter, 1977; Nonnecke and Smith, 1984; Reiter, 1983; Spik et al.,
1978), regulation o f Fe absorption (Fransson et al., 1983 and Kawakami et al., 1988),
growth promotion o f lymphocytes (Hashizume et al., 1983), product regulation of
macrophage, and granulocyte and neutrophil leukocytes (Ambruso et al., 1981;
Broxmeyer et al., 1980 and Hurlen et al., 1984), It could also control the development of
intestine by promoting cellular growth (Sanchez et al., 1992).
Structure of Lactoferrin
Lactoferrin is a monomeric, 80-kDa glycoprotein with a single polypeptide chain
of about 690 amino acid residues. It has a three dimensional structure comprised of two
folded globular lobes, known as the N-lobe and the C-lobe. The N-lobe and the C-lobe
share an internal amino acid homology of about 40% (Nuijens et al., 1996). A short ahelix peptide connects the lobes, and is the feature which readily distinguishes L f from
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transferrin. It is helical in Lf, but irregular and flexible in transferrin, containing several
proline residues (Baker and Baker, 2005).
Both the N-lobe and the C-lobe are divided into two regions. In each lobe, two
a/p domains referred to as N1 and N2, or C l and C2, enclose a deep cleft where the iron
binding site is located (Baker and Baker, 2005). The binding sites are comprised o f four
protein ligands (2 Tyr, 1 Asp, 1 His) that provide three negative charges, resulting in the
binding site being highly anionic (Baker and Baker, 2005). This results in their strong
affinity for cations such as Fe3+, with the three negative charges in the binding site
balancing for the three positive charges o f Fe . The two binding sites found on the Lf
molecule allow for one L f molecule to bind to two Fe3+ molecules.
It is suggested that the binding o f a carbonate anion occurs first, which allows for
the neutralization o f some positive charge near the iron binding site (Cowles et al., 2006;
Robblee et al, 2002). The helix N-termini face the interdomain cleft, making it somewhat
positively charged; H5 from N2 or C2 domain, serves as the binding site for essential
carbonate anion at the metal binding site (Baker and Baker, 2005). This non-protein
ligand (CO 3 2' ion), is responsible for determining the pH in which iron is released (Baker
and Baker, 2005). At a pH o f 3-4 protonation o f the carbonate ion occurs, causing a
weakening of the Lf- Fe3+ bond, resulting in the iron release (Baker and Baker, 2005).
Lactoferrin can be found in two forms, holo-Lf (iron bond) or apo-Lf (iron free).
The Lf found in secretions is almost entirely found in the apo-Lf state, with the capability
o f binding iron. The binding o f iron results in the conformational change o f the molecule
becoming more compact. There is a 55° rotation o f the N-lobe, and a 2 0 0 rotation of the
C-lobe (Baker et al., 1998). The two domains o f each lobe close over the bound metal
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and open to release it, resulting in the Lf-Fe3+ bond being reversible (Baker and Baker,
2005). The apo form is more flexible because it does not have two metal ions to lock the
lobes in place. The conformational changes associated with Fe3+ binding reduces the
interaction between the bactericidal domain o f Lf and the bacterial surface, thereby
abolishing its antibacterial activity (Dionysius et al., 1993). The bactericidal domain,
concentrated into a cluster o f positively charged residues near the N-terminus o f the Lf
molecule (Vorland et al., 1998; Elass-Rochard et al., 1998; Nibbering et al., 2001),
becomes less exposed in the holo-Lf configuration as opposed to the apo-Lf
configuration.
There are also structural differences between species, with bovine lactoferrin
sharing only 68% and 64% o f amino acid residues with the human and murine
lactoferrin, respectively (Nuijens et al., 1996). Depending on species the N- and C- lobes
differ significantly in their relative orientations (Moore et al., 1997). In addition, all Lf
appears to glycosylated, though with varying degrees from protein to protein, with human
L f having two glycosylation sites and bovine having four glycosylation sites (Baker and
Baker, 2005). The structural differences o f L f between species could result in some
activities o f L f being species specific.
Lactoferrin Receptors
The multiple biological functions o f L f depend on its target cells and on the
presence o f specific receptors (LfRs) at their surface (Suzuki et al., 2005). The
differences between tissues and cell types results in deferences in LfRs. Lactoferrin
receptors o f the small intestine in several neonatal species have been observed. However,
in order for LfRs to function in the small intestine, Lf must pass through the
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gastrointestinal tract without proteolytic degradation (Suzuki et al., 2005). The relatively
high pH and low enzyme secretion found in the neonate’s small intestine provide the
environment for L f to pass through (Suzuki et al., 2005). The elevated L f concentrations
found in colostrum and the environment of the neonates’ gastrointestinal system, indicate
L f may have a role in intestinal development. There is a variety o f suggested functions of
the small intestine LfR such as facilitating iron absorption, enhancement o f the immune
system, and stimulating mucosal differentiation. However, results from studies are
controversial and the mechanism is yet to be determined.
The binding o f L f to the LfRs on the brush border membrane vesicles (BBMV)
appears to be time dependent, saturable, and specific (Davidson et al., 1988; Hue et al.,
1988). However, it appears in some species such as the adult bovine that transferrin can
compete with L f to bind to the LfRs, thus reducing the percentage o f the L f that becomes
bound. (Talukder et al., 2003). Competitive binding experiments showed that hololactoferrin was more effective than less Fe-saturated forms of lactoferrin with regard to
receptor binding (Lonnderdal, 1995).
Antibacterial Properties of Lactoferrin
Lactoferrin has been shown to inhibit the growth o f many bacterial species, due to
both its bacteriostatic and bactericidal properties. Its bacteriostatic activity is related to its
ability to withhold iron w hile the bactericidal activity is not due to iron withholding. Iron
is essential for bacterial growth; when L f is present it binds the iron making it unavailable
for the bacteria, resulting in the inhibition o f bacterial growth (Dionysius et al., 1993).
The apo-Lf found in the extracellular compartments within the host body or host mucosal
surfaces binds iron, resulting in the level of iron being below the required amount to
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support microbial growth (Finkelstien et al:, 1983). However, most pathogenic bacteria
have developed ways in which they can overcome Lf- generated iron deprivation by
acquiring iron by means o f two principal systems: either secreting small iron chelators
(siderophores) or acquiring iron directly from host transferrin and L f (Valenti and
Antonini, 2005). The siderophores compete with L f for iron, which then reduces the
growth-inhibiting effect o f the protein. In the case o f acquiring iron directly from Lf, this
involves binding L f to bacterial receptors found on the bacteria (Gray-Owen et al., 1996).
The Lf-bacteria binding causes a confirmation change in Lf, which lowers the affinity of
Lf the C-lobe for iron (Ekins et al., 2004).
Bactericidal properties have also been shown in which there is a direct interaction
between L f and bacterial surfaces (Arnold et al., 1977). A non-specific binding between
Lf and bacterial surfaces, o f both Gram-negative and Gram-positive species, are caused
by the high density o f charges found on the surface o f the Lf molecule (Baker et al.,
2002). Lactoferrin binds to the porins present on the outer membrane o f Gram-negative
bacteria (Gado et al., 1991), resulting in the release o f lipopolysaccharides. This will
enhance the susceptibility of the bacteria to osmotic shock, lysozymes, and other
antibacterial molecules (Leitch and Willcox, 1998). In the case o f Gram-positive bacteria
its effect is likely to be similar to that of cationic and amphipathic antibacterial peptides
(Valenti and Antonini, 2005). The positively charge L f molecule binds to the negatively
charge lipid matrix found in the membrane o f Gram-positive bacteria through
electrostatic interactions while the amphipathic residues disturb the non-polar membrane
interior due to hydrophobic interactions (Giangaspero et al., 2001; Wessolowski et al.,
2004).
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Lactoferrin from several mammalian species have been shown to inhibit the
growth o f a number of bacteria, including human and/or animal pathogenic strains of E.
coli, Salmonella typhimurium, Shigella dysenteriae, Listeria monocytogenes,
Streptococcus spp., Vibrio cholerae, Legionella pneumophila, Klebsiella pneumonia,
Enterococcus spp., Staphylococcus spp., Bacillus stearothermophilus and Bacillus
subtilis (Valenti and Antonini, 2005). Lactoferrin reduces the growth o f harmful bacteria
in the gastrointestinal tract, while promoting growth o f bacteria such as Lactobacillus and
Bifidobacteria which are believed to be beneficial to the animal (Valenti and Antonini,
2005).
Antiviral Activity of Lactoferrin
Since 1994, potent antiviral activity o f human L f and bovine L f has been
demonstrated against both enveloped and naked viruses (Valenti and Antonini, 2005).
Lactoferrin has been shown to have an effect on a variety of viruses in vitro such as
cytomegalovirus, herpes simplex virus, human immunodeficiency virus, human hepatitis
C and B viruses, rotavirus, and adenovirus (Valenti and Antonini, 2005).

Lactoferrin

may exert its effects by inhibition o f viral fusion and entry into the cell, rather than
stimulation o f the immune system. Lactoferrin has been shown to inhibit antigen
synthesis by the virus, it can interfer with the earlier stage of the virus (Superti F et al.,
1997). The antiviral activity of L f is the result o f its strong affinity for heparin sulfate
and glycosaminoglycan, carbohydrates that are the typical viral binding sites on the cell
membrane (Andersen et al., 2001).
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Antifungal and Anti-parasitic Activity of Lactoferrin
The effect o f L f on fungus is believed to be caused from adsorption to the cell
surface rather than iron deprivation (Valenti et al., 1986). In vitro studies have shown
that human Lf, bovine Lf, and lactoferricin are able to fight pathogenic fungi (Valenti and
Antonini, 2005). The Candida species o f fungi has been the most exclusively studied in
Lf studies. The L f growth-inhibitory effect appears to be much higher then those of most
antifungal drugs currently available (Valanti and Antonni, 2005). The peptide
lactoferricin either has two antifungal mechanisms, direct fungicidal activity or up
regulation o f the host defense (Gifford et al., 2005).
Anti-parasitic activities are complex and at this date unclear. In some species
such as Pneumocytis carini L f appears to interfere with iron acquisition, while in other
species such as Tritrichomonas foetus it appears to act as an iron donor, thus enhancing
infection (Tachezy et al., 1996). In the case of lactoferricin, evidence indicates it may be
attracted to the surface, resulting in the disruption o f the membrane or the release of
parasitic structural components that subsequently activate host defense systems (Gifford
et al., 2005).
Antitumor Activity of Lactoferrin
Lactoferrin and lactoferricin have both been shown to have anti-tumor effects
against leukemia (Yoo et al., 1997; Yoo et al., 1997), fibrosarcomas, melanomas and
coloncarcinomas (Eliassen et al., 2002), without affecting normal fibroblasts and
erythrocytes (Gifford et al., 2005). The changes, which occur in the membrane, such as
exposure of phosphatidylserine, o f a tumor, cell results in Lfcin targeting the cell (Fadok
et al., 2001). The bond o f Lfcin to the cancer cell disrupts the membrane marking,
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resulting in apoptosis (Aramaki et al., 2000). Lactoferrin itself has been shown regulate
natural killer cells (Damiens et al., 1998; Shau et ah, 1992; Bezault et ah, 1994), G1
protein modulation (Damiens et al., 1999), and inhibition o f vascular endothelial growth
factor (VEGF)-mediated angiogenesis (Norrby et ah, 2001).
Anti- Inflammatory Activity of Lactoferrin
Lactoferrin has the ability to inhibit an inflammatory response through a variety
of ways. First, L f can bind free iron that has accumulated in inflamed tissues and
catalyzes the production o f tissue-toxic hydroxyl radicals (Legrand et ah, 2005). The
PMN’s release o f the apo-Lf at the inflamed site, because o f its iron-binding stability at
low pH, it can precipitate in iron homeostasis and detoxification (Legrand et ah, 2005).
Other anti-inflammatory properties involve its ability to inhibit the release of cytokines,
which induce recruitment and activation o f immune cells at inflammatory sites. It is able
to reduce the release o f inflammatory cytokines by binding to the lipopolyscharide
membrane o f bacteria, through its lactoferricim domain (Appelmelk et ah, 1994;
Brandenburg, 2001; Elass-Rochard et ah, 1995), resulting in the neutralization o f LPS
activity (Mattsby-Baltzer et ah, 1996; Zhang et ah, 1999). Lactoferrin is also considered
a marker o f inflammatory disease because its concentration increases during
inflammatory diseases such as septicemia (Bennet et ah, 1978), rheumatoid synovitis
(Caccavo et ah, 1999), bowel disease (Kane et ah, 2003), and neurodegenerative disease
(Fillebeen et ah, 2001).
Lactoferrin Effect on Intestinal Development
Previous research with other species such as the human infant indicates that LF
has a stimulatory effect on cell proliferation, increased cell size and growth o f gut-
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associated lymphatic follicles (Artym and Zimecki, 2005). The weight o f the small
intestine o f neonatal mice has been shown to increase by about 27% when they consumed
milk containing 12 mg/mL o f human lactoferrin (Zhang et a l, 2001). In the same study
by Zhang et al. (2001), the intestinal length increased only by about 6.5% indicating Lf
enhances mucosal growth. In a study by Humphrey et al. (2002), greater villous height
and fewer leukocytes were observed in the lamina propria in chicks when 5% Lf
(0.125g/kg) and 10% lysozyme (0.3g/kg) were added to the diet. The increased villous
height and surface area resulted in better nutrient digestion and absorption, thus
improving feed efficiency. The fewer leukocytes were the result o f a decrease of
microbial challenges, thus improving intestinal health. The 5% L f alone had no effect,
while 10% lysozyme only had a slight increase on intestinal development. The
combination o f L f and lysozymes resulted in a synergistic effect, by L f causing the
release o f LPS, which enhances the bacteria’s susceptibility to lysis by lysozymes
(Humphrey et al., 2002). In calves, the data o f L f having a role on intestinal development
is controversial. Joslin et al. (2001) and Robblee et al. (2002) found feed efficiency to
increase when L f was supplemented to milk replacer, while Cowles et al. (2006)
observed no effect o f L f on xylose and glucose absorption.
Lactoferrin in the Mammary Gland
The biological roles of L f to modulate the control o f macrophage, lymphocytes,
and neutrophil function and its antibacterial properties aid in the immunity of the
mammary gland (Sanchez and Watts, 1999). Lactoferrin concentrations increase in
mammary secretions o f dairy cattle during mastitis and mammary involution (Harmon et
al., 1976;, Rejman et al., 1989; Welty et al., 1976). Mammary involution is a critical time
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for restoring mammary health. It is estimated that mastitis costs the dairy industry two
billion dollars per year. Incidence o f mastitis is particularly high in dairy cows during
early involution, but the gland becomes more resistant to infection in the mid dry period
(Oliver and Sordillo, 1989). The concentration o f L f increases from 0.4 mg/mL at drying
off to 20 to 30 mg/mL by 30 d o f involution (Smith and Oliver, 1981; Smith and
Schanbacher, 1977), and by 30 fold during acute bovine mastitis (Schanbacher et al.,
1993,1997), indicating L f may play a role in protecting against intramammary infection.
Cows are commonly treated at dry-off with a combination o f penicillin and
novobiocin to protect against intramammary infection (Sanchez and Watts, 1999).
Novobiocin is able to inhibit the growth of Gram positive bacteria but not Gram negative
bacteria due to its inability to penetrate the lipopolysaccharide membrane (Oram et al
1996). However, L f has been shown to damage the outer membrane o f Gram negative
bacteria by causing the release o f LPS molecules from the outer membrane. The increase
o f L f during involution may result in L f disruption o f the membrane o f bacteria such as
E. coli. This would result in novobiocin attacking Gram negative bacteria and destroying
them. Although Sanchez and Watts (1999) showed that there was a synergistic effect
between L f and novobiocin in on E. coli bacteria in vitro, there was no reduction in
bacterial counts in vivo.
Diarra et al. (2001) compared the effect o f L f in combination with penicillin on
the morphology and the physiology o f Staphylococcus aureus isolated from bovine
mastitis. Staphlyococcus aureus is an important human and animal pathogen that is the
most common cause o f bovine mastitis, causing a loss of milk production (Forsmen et al.,
1997). Diarra et al., (2001) found that combining penicillin with relatively low
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concentrations o f bovine lactoferrin lead to the synergistic increase o f the antibacterial
activity o f this antibiotic to Staphlococci strains isolated from clinical bovine mastitis.
There was no effect when penicillin was used as the only treatment due to the bacteria’s
resistance to the antibiotic and L f alone only had a small inhibitory effect. Although the
two combined in vitro can induce destruction o f the bacteria, the mechanism o f action is
not yet estabilished (Diarra et al., 2001).
The loss of the synergistic effect in vivo may be due to decreased activity of
antibiotics, or the L f present in bovine mammary secretions during involution exist as
complexes with other macromolecules, which may alter L f antibacterial activity (Wang
and Hurley, 1998). Lactoferrin commonly binds to macromolecules, such as Ig, casein,
secretory components, albumin, lysozyme, and (3-LG (Hurley, 1993; Lampreave et al.,
1990), as well as to DNA and heparin (Zou et al., 1992). The biochemical nature and
functional significance o f complexes between L f and other macromolecules are
unknown, but the may reduce L f antimicrobial activity, or when bound to Ig, they may
enhance antimicrobial activity (Wang and Hurley, 1998). However, human Lf and IgA
act cooperatively with increased bacteriostatic activity (Stephens et al., 1980).
Lactoferrin Fed to Dairy Calves
A dairy calf is exposed to a variety o f pathogens that result in illnesses such as
respiratory disease and scours. The biological functions o f L f as discussed could have
multiple benefits in fighting these diseases However, the research involving feeding Lf
to dairy calves has resulted in conflicting data.
The effect o f supplemental L f (0,1, lOg/d) in a conventional milk replacer on
preweaning growth, blood, and health characteristics was studied by Joslin et al. (2002).
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Results indicate that calves receiving supplemental L f had higher starter intakes,
increased average daily gains, and increased heart girth measurements. It was also shown
that calves fed 1 g/d o f L f had greater average daily gains then calves fed the 10 g/d
treatment. The follow up study o f Robblee et al. (2003) was designed to determine the
optimum level o f L f to achieve the greatest response in health, growth and weaning of
dairy calves. W hen supplementing non-medicated milk replacer with 0, 1, 2, or 3 g o f Lf
per day, results indicated lg/d o f L f was the optimum level for good calf performance.
Preweaning fecal scores and total days medicated showed a quadratic response w ithlg
having the lowest score. There was also a linear effect in calves supplement with LF on
the preweaning average daily gain and feed efficiency, however it did not maintain the
same effect postweaning. These studies indicate that lg/d of supplemental Lf would be
beneficial to the dairy calf, possibly by aiding in the immune system o f calves by
destroying pathogens, which may result in illness. However, in a study conducted by
Cowles et al. (2006), in which they compared the effect o f 0 or lg/d o f L f in both a
conventional or intensified milk replacer, there was no increase in starter consumption,
average daily gain, feed efficiency, or fecal scores between L f treatments. The difference
in results between studies could be caused by the difference in days medicated. In the
study by Cowles et al. (2006), Calves had at least 50% lower fecal scores and day’s
medicated then calves used by Joslin et al. (2002). These findings indicate that
supplemental L f is only beneficial when calves are sick
Not only would the antibacterial properties o f L f be beneficial to the dairy calf,
but its ability to influence the development o f intestinal epithelia would also be
considered beneficial (Nicholas et al., 1987; Van Leeuwen et al., 2000). The theory
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being if L f increases intestinal development, then nutrient absorption will increase.
Schottstedt et al. (2005) investigated the effects o f dietary bovine L f and vitamin A alone
or in combination on epithelia of the small intestine and colon and on the gut-associated
lymphoid tissues, especially o f Peyer’s patches (PP). In this study, they found a variety
of positive and negative results depending on which location o f the GIT was measured.
First, plasma L f concentrations in all formula plus L f fed calves remained low, indicating
Lf was not absorbed. It was also found that crypt cell proliferation o f the colon was
negatively affected by L f supplementation. However, the duodenum o f calves fed the
formula supplemented with Lf had a thicker tunica muscularis layer then calves fed
colostrum, indicating that orally administered L f might have an effect on both protein
synthesis (Burrin et al., 1996) and on GIT muscle synthesis.
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CHAPTER II

Serum IgG Concentration of Neonatal Calves Fed Colostrum Replacer
Supplemented with Lactoferrin
Introduction
The neonatal calf is bom hypogammglobulinemic. Successful passive immunity is
dependent upon adequate consumption and absorption o f IgG soon after birth. Passive
immunity is reliant on a variety o f factors such as quality and quantity o f colostrum fed
(Morin et al., 1997), apparent efficiency of IgG absorption (AEA) (Morin et al., 1997),
age of first feeding (Stott et al., 1979), stress (Hough et al., 1990; Johnston and Stewart,
1986; Stott, 1980), and method o f feeding (Lateur-Rowet and Breukink, 1983).
Successful passive transfer is defined as having a blood serum concentration o f > 10 mg
of IgG/mL at 24 h after birth. Blood serum concentrations < lOmg o f IgG/mL at this
time are related to calf morbidity and mortality (Besser and Gay, 1994), as well as long
term depressed calf performance (Wittum and Perino, 1995). The national dairy heifer
evaluation project found that 40% o f all calves sampled between 24 and 48 h had an IgG
concentration o f < lOmg/mL and over 25% < 6.2mg/mL (Wells et al., 1996). There is a
need for improvement o f management procedures on the farm and development of
products that will increase the number o f calves that acquire passive immunity
(Arthington et al., 2000).
The recognition of high rates o f failure o f passive transfer and the risk of
transferring disease to calves through maternal colostrum has led to areas o f research,
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evaluating alternative sources o f maternal colostrum. Maternal colostrum is the best
source o f Ig and nutrients for the calf. However, good quality colostrum is not always
available. Alternative sources o f providing Ig and nutrients to the calf have been
developed such as colostrum replacer (CR) and colostrum supplements. These products
are derived from a variety o f sources such as lacteal secretions, blood serum, and eggs.
Colostrum replacer is defined as containing > 100 g IgG/dose and providing other
nutrients required by the calf (Quigley et al., 2002a). A colostrum supplement contains <
100 g IgG/dose and is not formulated to replace maternal colostrum but rather be fed with
it (Quigley et al., 2002a). Supplements do not provide the necessary energy, amino acids,
or vitamins and minerals necessary for the c a lf s development. Although CR contain the
required amount o f lOOg o f IgG when fed at recommended levels, no milk or colostrum
based replacer product has routinely shown results o f serum IgG concentrations >
lOmg/mL in dairy calves (Garry et al., 1996; Mee et al., 1996; Hopkins and Quigley,
1997; Arthington et al., 2000). The reason for poor IgG absorption o f colostrum
replacers and supplements has yet to be determined. Colostrum replacer not only needs
to replicate maternal colostrum in its energy, protein, fat, mineral and vitamin content,
but also other bioactive proteins such as lactoferrin (Lf). , Lactoferrin is an iron binding
glycoprotein present in colostrum and milk. The concentration o f L f in bovine colostrum
is 1 to 2 mg/mL, compared to bovine milk which only has a concentration of 0.01 to 1
mg/mL (Molenaar et al., 1996). Lactoferrin has been shown to be important for intestinal
development and development o f the immune system in species such as mice and humans
(Shah, 2000). It has three functions, which may be beneficial to the development of a
neonatal calf: inhibiting bacterial growth (Teraguchi et al., 1994), increasing intestinal
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cell growth (Zhang et al., 2001), and stimulating glucose absorption (Teraguchi et al.,
1998). The ability o f L f to inhibit bacterial growth may protect the intestine o f the
newborn calf from infection, while increasing intestinal cell growth may increase both
IgG and nutrient absorption by the intestine (Robblee et al., 2003). White (2005) saw an
effect o f L f on average apparent efficiency o f absorption (AEA), when calves were fed
maternal colostrum with lg/d of supplemental Lf. The objective o f this experiment was
to determine the effect o f various levels of L f supplementation to colostrum replacer fed
as 1 or 2 doses on apparent efficiency o f IgG absorption, serum IgG concentrations, and
intestinal development in neonatal Holstein bull calves.
Materials and Methods
Calves, Feeding, and Treatments
This experiment was reviewed and approved by the University o f New Hampshire
Institutional Animal Care and Use Committee (Approval # 051102).
A total o f 80 Holstein bull calves bom between March 2006 and November 2006
at two different dairies were used. Calves were assigned randomly at birth by location to
a 2 x 4 factorial arrangement o f treatments in a randomized complete block design.
Calves were blocked in groups o f 8 at birth by location. Randomization o f treatments
occurred within blocks. Forty-eight bull calves assigned to the experiment were bom at
the University o f N ew Hampshire, Fairchild Teaching and Research Center (initial BW
of 43.8 + 4.9 kg). Thirty-two calves were from a local New Hampshire dairy farm. All
calves were removed from their dam and not allowed to suckle. Calves born at the
university were weighed at birth and placed in a naturally ventilated, enclosed calf room
in individual pens. Pens were bedded with kiln-dried sawdust. Calves born at the
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commercial dairy were not weighed at birth, as a scale was unavailable. Calves from the
commercial dairy were placed in a naturally ventilated maternity pen and bedded with
wheat straw. The treatment groups consisted o f 1 dose1 o f CR versus 2 doses of CR with
or with/out supplemental L f (Immucell, Portland ME). The levels o f supplemental Lf
were 0, 0.5, 1, or 2 g/d. All calves received 1 dose1 o f CR with or without supplemental
Lf within 90 min o f birth. The source o f L f was bovine milk (Immucell Corp., Portland,
ME); iron saturation was 13.2g/100g. The second feeding was at 12 h in which the calves
received either a second dose1 o f CR or 2 L o f non-medicated milk replacer (MR)
(20%CP:20%fat) with each containing the varying levels of supplemental L f depending
on which treatment the calf was assigned. Calves continued to be fed MR with or
without supplemental L f in 12 h increments throughout study. Calves received 1.2% of
its initial BW, in MR powder. The MR powder was divided into two equal portions, and
each portion was reconstituted in 2 L o f warm water immediately before feeding. At the
sixth feeding in which calves were 60 + 2 h of age, a xylose challenge was conducted
(university calves only) to determine xylose absorption by the small intestine. Calves
from the commercial dairy were removed from study at 48 h, while calves bom at the
university were removed by 72 h.
Feed Analysis
The DM o f the CR and MR was determined by drying samples in the same
forced-air convection oven at 60°C for 24 h. Samples from each bag of CR and MR were
saved and stored at -20 °C. When the experiment was completed, samples were
composited for nutrient analysis. Colostrum replacer and MR were analyzed for CP
(AOAC, 1979), fatty acid (AOAC, 1995), and Ca, P, Mg, and Fe (AOAC, 1990), and Lf
1 1 dose is equal to 470g o f CR reconstituted in 1L o f warm water
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after reconstituting the M R to 15% DM (RID; Cardiotech). Chemical analysis of CR and
MR are shown in Table 1.
Blood Collections for Immunoglobulin G and Serum Protein
Blood samples were collected via jugular venipuncture before the first feeding of
colostrum replacer (within 90 min o f birth, referred to as 0 h) and at 6, 12, 18, 24, 48 h
after birth. Samples were collected in 5-mL tubes. Samples were allowed to clot at room
temperature for at least 1 h and then centrifuged at 3300-x g at 25°C for 20 min. Serum
samples were stored at -20°C until analyzed for IgG by radial immunoassay (WCVM,
Saskatoon Canada) and total serum proteins with a digital refractometer (SPER
Scientific, model 300027 from VWR).
Blood Collections for Xylose Challenge
The xylose challenge was only performed on calves bom at the UNH Fairchild
Dairy Teaching & Research Center. D-xylose (0.5g/kg BW) was mixed with the MR and
fed at the sixth feeding (60 + 2 h o f age). D-xylose is used as an indirect marker for
glucose absorption across the small intestine. Calves were fasted throughout the sampling
period but allowed access to ad libitum water.

Blood samples were taken before D-

xylose treatment (0 h) and at 2, 4, 6, 8, and 12 h after feeding. Blood samples were
collected into evacuated tubes via jugular venipuncture, containing tripotassium EDTA,
to measure D-xylose and glucose concentrations in the plasma. Glucose levels were
measured in the same blood samples to compare xylose and glucose concentrations.
Blood samples were immediately centrifuged at 3300 x g at 5°C for 20 min to harvest
plasma. Two aliquots of plasma were stored in 5-ml polypropylene tubes at -20°C and
later analyzed for D-xylose and glucose concentrations.

D- xylose was measured as
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described by Merritt and Duelly (1983). Plasma glucose concentrations were determined
using a glucose oxidase base kit (Wako, Richmond VA).
Measurements:
Apparent efficiency o f IgG absorption (AEA) at 0, 6, 12, 18, 24 h of age was
estimated using the equation: (plasma IgG [g/L] x body weight [kg] x 0.09/IgG intake) x
100% (Quigley et al., 1998a). The IgG concentration, area under the curve (AUC), and
mean IgG were analyzed. Total serum protein concentrations were also analyzed. The
blood samples collected on d 3 at 0 ,2 , 4, 6, 8, and 12 h were analyzed for the
concentration mean and AUC for both D-xylose and glucose.
Statistical Analysis:
A randomized complete block design with a 2 x 4 factorial arrangement of
treatments was used, and calves were randomly assigned to treatments in blocks of eight
based on birth order and location. Analysis o f varience was conducted using the MIXED
procedure o f SAS (SAS Institute, 2001). The mixed model effect used was:
Y jjk = p + bi + Lj + Rk + LRjk + KCjjk + Ejjk
Where:
Y = the dependent variable,
\x = the overall mean,
bj = the random effect o f block i (i = 1,...10),
Lj = the fixed effect o f the j* lactoferrin level ( j = 0, 0.5, 1,2),
Rk = the fixed effect o f kth colostrum replacer feeding (k = 1,2),
LRjk = the fixed effect o f the interaction between the j th lactoferrin level and the kth
colostrum replacer feeding,
K = the regression coefficient o f the covariate C
Cjjk = is the covariate variable for the 1th calf, o f the ith block, o f the j th lactoferrin level,
kl colostrum replacer feeding (1 = 1,...8), and
Ejjk is the random residual ~N(0,o2e).
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Significance was determined at a P < 0.05. Data were tested for linear, quadratic,
and cubic response to level o f L f supplementation. Degrees o f freedom were determined
using the Satterwaite option of the MIXED procedure o f SAS (SAS® Institute, 2001).
Results
Chemical analysis o f CR and MR are presented in Table 1. The L f content of CR
was 0.78g/dose and the lactoferrin content o f MR was 0.45 mg/g o f DM.
Calves fed two doses of CR had higher mean serum IgG concentrations (P <
0.001) and total serum protein (P < 0.01) compared to calves fed one dose of CR (Table
2). Calves fed a second dose of CR at 12 h had higher plasma IgG and total serum protein
levels at 18, 24, and 48h, resulting in a significant feed x time interaction (P < 0.05)
(Figure 1 and 2). On average, calves attained blood serum IgG concentration > 1 0 mg/mL
resulting in successful passive transfer by 24 h, except for calves fed 1 dose o f CR + 1 or
2 g/d o f supplemental Lf. The proportion o f calves that attained passive IgG transfer per
treatment is shown in Table 2. There were no effects o f Lf supplementation on serum IgG
concentrations and total serum protein concentrations. Area under the curve of IgG
(Table 2) was greater for the calves fed 2 doses CR compared to the calves fed 1 dose CR
(T O .0001). Lactoferrin supplementation had no effect on the results for AUC o f IgG.
There was a decrease (P < 0.0001) in AEA o f IgG when 2 doses of CR were fed
versus 1 dose o f CR (Table 2). Apparent efficiency o f absorption o f IgG decreased
quadratically (P < 0.05) with increasing levels o f L f (Table 2).
Two hours after xylose intake, plasma xylose concentrations were higher in calves
fed two doses o f CR (P < 0.01), although at 8 and 12 h after xylose intake (P<0.05)
plasma xylose concentrations were higher in the calves fed one dose o f CR (Figure 3).
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However, the overall mean for plasma xylose concentrations o f all the time points’ were
not different between calves fed one dose verses calves fed two doses o f CR (Table 2).
Plasma xylose concentration and AUC for xylose decreased quadratically (P <0.01) with
increasing L f supplementation (Table 2). There was a trend (P < 0.1) for plasma glucose
with calves fed two doses o f CR to have higher concentrations o f plasma glucose then
calves fed 1 dose o f CR. There was no effect o f L f on glucose concentrations (Table 2).
Discussion
Serum IgG concentration can be affected by dystocia (Donovan et al., 1986) and
by birth weight, with larger calves having lower IgG concentrations on average because
of they have higher plasma volumes (Quigley et al., 1998). In this experiment, there
were no differences among treatments in calf birth weights or calving scores.
In this study, on average calves attained blood serum IgG concentration > 10
mg/mL resulting in successful passive transfer by 24 h, except for calves fed 1 dose of
CR + 1 or 2 g/d of supplemental Lf. This is different from other studies in which it was
observed that lacteal secretion based CR did not consistently provide successful passive
transfer (Zaremba et al., 1993; Garry et al., 1996; Mee et al., 1996; Hopkin and Quigley,
1997; Arthington et al., 2000). However, the number o f calves which attained passive
transfer was higher when fed 2 doses o f CR vs 1 dose CR (P = 0.03). The AEA o f IgG
was lower in calves fed 2 doses o f CR, perhaps the result o f more IgG supplied then the
calves were able to absorb.
The purpose of adding L f to the CR was to determine if the quality o f CR could
be improved by increasing IgG absorption. A previous study conducted in our
laboratory (White, 2005) showed an effect o f L f on average AEA over time, when bull
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calves were fed maternal colostrum with lg/d o f supplemental L f However, at 24 h only
there was no effect o f L f on AEA o f IgG. The present study showed no effect o f L f on
serum IgG concentration but there was a suppressing quadratic effect (P<0.05) on AEA
o f IgG with increasing levels o f Lf. White (2005) added 1 g/d o f L f to maternal
colostrum, which has an average o f about 2 mg/mL o f L f (Molenaar et al., 1996). The
calves received 2 feedings (2L/feeding) o f maternal colostrum bringing the total Lf
consumed to be about 9 mg/mL. In the present study, L f was added to CR which only
had an L f concentration of 0.78g/dose o f CR so at the highest supplementation o f 2g
these calves were still receiving less L f then the calves used by White (2005). In addition,
maternal colostrum may have other nutrients such as vitamins and other bioactive
proteins that may aid in IgG absorption and intestinal development that may not be
present in the CR.
The decrease in AEA o f IgG when L f was supplemented to CR may have been
caused by L f ability to bind to Ig such as IgG and IgA prior to absorption(Wang and
Hurley, 1998). This would increase the overall size of the molecule, thus possibly
decreasing it ability to be absorbed. Other components found in maternal colostrum may
compensate for this effect, resulting in Lf not hindering IgG absorption as shown by
White (2005). The complexes between Lf and other proteins may either enhance or
reduce its biological functions (Wang and Hurley, 1998). In the case o f L f binding to
IgA, there is a synergistic effect on bacteriostatic activity (Stephans et al., 1980) but the
Lf-casein complex decreases the antibacterial activity o f L f (Ellison and Giehl, 1991;
Hurley, 1993).
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There was a decreasing quadratic effect (P O .O l) with increasing Lf
supplementation on xylose absorption and AUC with calves fed 0.5 and lg o f L f having
lower plasma xylose concentration than calves fed 0 and 2 g o f Lf. The xylose absorption
test is used as an indirect measurement of glucose absorption, intestinal epithelial size
and function (Hammon and Blum, 1997; Kuhne et al., 2000; Rauprich et al., 2000). The
results from this study indicate that L f is impairing xylose absorption and possibly
intestinal development when supplemented at 0.5 and 1 g per day for the first 3 days of
life. Cowles et al. (2006) also performed a xylose challenge on calves fed MR
supplemented with 1 g/d of L f and found no effect o f Lf. However, calves were 10 days
old at the time o f the xylose challenge and only fed one level o f L f at lg/d added to either
a nonmedicated conventional MR (20% CP: 20% fat) or a nonmedicated intensified MR
(28% CP:20% fat). These authors reported no effect o f feeding the lg/d o f Lf on xylose
absorption while in the present study both 0.5 and lg/d o f L f had a negative impact on
xylose absorption. The maximum L f fed per feeding was 1.78 mg/mL in the present
study compared to Cowles et al. (2006) in which the maximum L f fed per feeding was
1.05 mg/mL.
This is contradictory to other studies in which L f was observed to increase
intestinal development (Zhang et al., 2001; Humphrey et al., 2002). However, Zhang et
al. (2001) fed milk from transgenic dams to neonatal mice for 10 d. The milk from these
transgenic dams had a L f concentration of 12 mg/mL. Zhang et al. (2001) fed Lf at a
much higher concentration and for a longer period o f time than in the current study.
Humphrey et al. (2002) observed greater villous height, better nutrient absorption, and
greater feed efficiency in chicks when L f was fed in combination with lysozyme. There
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wasjno effect on intestinal development when L f was fed alone. These studies would
indicate that if the neonatal calf responded in the same way as neonatal mice and chicks
than Lf would have to be fed at a much higher concentration or in conjunction with
another component o f maternal colostrum such as lysozyme.
Conclusion
Calves can attain successful passive transfer when fed 1 dose of a lacteal based
CR. However, feeding calves 2 doses o f CR is recommended to provide a margin of
safety due to factors affecting absorption. The AEA o f IgG in CR is not improved by
Lf supplementation at the levels fed. Lactoferrin does not increase xylose absorption
in the calf at the levels fed; suggesting intestinal development is not improved by Lf
supplementation. More research needs to be done to determine the components in
maternal bovine colostrum that affect intestinal development and IgG absorption.
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Tablel. Nutrient analysis on a DM basis o f Colostrum Replacer and
Milk Replacer______________________ __________________________
Item
MR2
CR1
89.5
DM, %
93.5
54.9
20.6
CP, %
18.9
Fat ( acid hydrolysis),%
22.6
0.97
Ca, %
1.1
0.64
0.99
P, %
0.15
0.16
Mg, %
102
Fe, ppm
0.78g/dose
0.48mg/g
Lactoferrin (g/dose3)
Land O Lakes colostrum replacer, Saskatoon, SK, Canada
2 Blue Seal Feeds non-medicated milk replacer, Londonderry, NH
3 1 dose is equal to 470 g with > lOOg o f bovine IgG
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Table 2: Overall means of IgG, serum protein, xylose and glucose. Apparent efficiency of absorption of IgG and area under the curve for IgG,
xylose, and glucose.______________________________________________________________________________________________ _______

T r e a tm e n ts 1
1 CR2
Item
SPT, %
Serum, IgG7 g/L
Avg.

24-h
Serum Protein7 (g/L)
Avg.

24-h
AUC lgG7(g/L'h)
AEA8, %
Xylose8 (mmol/L)
AUC Xylose8 (mmol/dL-h)
Glucose8 (mg/dL)
AUC Glucose8 (mg/dLh)

0
0.8

0.5
0.79

1
0.7

9.7
10.7

9.0
10.3

8.8
9.7

2 CR
Lactoferrin
2
0
0.9
0.4

0.5
0.79

1
0.9

2
0.9

11.2
14.5

10.3
13.1

11.3
14.5

10.8
14.1

0.64
1.00

< 0.001
< 0.001

NS
NS

NS
NS

4.9
5.1
5
5.1
5.4
5.3
5.5
5.4
3306.2 2449.9 3459.5 3099.8
29.0
33.0
26.0
28.0
2.0
1.8
1.9
2.0
28.2
29.3
22.3
24.6
104.7
103.5
106.6
99.5
66586.0 70293.0 67823.0 61614.0

0.10
0.14
370.9
2.99
0.09
1.9
3.49
5457.0

< 0.001
< 0.001
< 0.0001
< 0.0001

NS
NS

NS
NS

NS
NS
NS
NS
NS
NS

NS

8.1
8.7

4.9
4.8
4.9
4.8
4.9
4.7
5.0
4.6
2160.1
1875.9 1827.4 1442.9
34.0
39.0
44.0
41.0
2.1
1.8
1.9
2.0
26.7
31.3
24.3
26.9
103.9
100
95.8
96.9
66989.0 62349.0 57835.0 59067.0

C o n tr a sts3
SE

CR Effect4

Linear

0.13

0.03

NS6

Calves were fed either 1 dose of CR or 2 doses of CR with either 0, 0.5, 1, or 2 g/d of lactoferrin in the first two feedings.
2CR = colostrum replacer
3Contrast: linear and quadratic effects of lactoferrin.
4 Main effect of colostrum replacer.
5 SPT = Proportion o calves that attained successful passive IgG transfer > 10g/L
6P<0.05.
7 Data collected from all 80 calves collected from both dairies.
8Data collected from 48 calves from University of New Hampshire dairy.
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Figure 1: Serum IgG concentrations (mg/mL) o f calves fed either I or 2 doses o f CR with varying levels o f lactoferrin over the first
48h of life. 1L0 = 1 dose CR + Og of lactoferrin, 1L0.5 = 1 dose CR + 0.5g o f lactoferrin, 1L1 = 1 dose CR + lg of lactoferrin, 1L2 =
1 dose CR + 2g of lactoferrin, 2L0 = 2 dose CR + Og o f lactoferrin, 2L0.5 = 2 dose CR + 0.5g o f lactoferrin, 2L1 = 2dose CR + lg o f
lactoferrin, 2L2 = 2 dose CR + 2g of lactoferrin. The largest SEM was 0.87 and occurred in calves fed 1L2 for all time points.
* (P < 0.05) Calves fed two doses o f CR had greater plasma IgG.
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Figure 2: Serum Protein concentration (mg/mL) o f calves fed either 1 or 2 doses o f CR with varying levels o f lactoferrin over the first
48h of life. 1L0 = 1 dose CR + Og o f lactoferrin, 1L0.5 = 1 dose CR + 0.5g o f lactoferrin, 1L1 = 1 dose CR + lg o f lactoferrin, 1L2 =
1 dose CR + 2g of lactoferrin, 2L0 = 2 dose CR + Og o f lactoferrin, 2L0.5 = 2 dose CR + 0.5g o f lactoferrin, 2L1 = 2dose CR + lg o f
lactoferrin, 2L2 = 2 dose CR + 2g o f lactoferrin. The largest SEM was 0.13 and occurred in calves fed 1L2 for all time points.
* ( P < 0.05) Calves fed two doses o f CR had greater serum protein.
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Figure 3: Plasma xylose concentration (mg/mL) o f calves fed either 1 or 2 doses o f CR with varying levels of lactoferrin over the first
48h o f life. 1L0 = 1 dose CR + Og o f lactoferrin, 1L0.5 = 1 dose CR + 0.5g o f lactoferrin, 1L1 = 1 dose CR + lg o f lactoferrin, 1L2 =
1 dose CR + 2g of lactoferrin, 2L0 = 2 dose CR + Og o f lactoferrin, 2L0.5 = 2 dose CR + 0.5g o f lactoferrin, 2L1 = 2dose CR + lg o f
lactoferrin, 2L2 = 2 dose CR + 2g of lactoferrin. The largest SEM was 0.15 and occurred in calves fed 1L1 for all time points.
* (P <0.01) Calves fed two doses of CR had higher plasma xylose concentrations and a quadratic response to lactoferrin with 0.5g/d
and lg/d being less than 0 and 2 g/d.
+(P<0.05) Calves fed one dose o f CR had higher xylose concentrations.
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Figure 4: Plasma glucose concentration (mg/mL) o f calves fed either 1 or 2 doses o f CR with varying levels o f lactoferrin over the
first 48h o f life. 1L0 = 1 dose CR + Og o f lactoferrin, 1L0.5 = 1 dose CR + 0.5g o f lactoferrin, 1L1 = 1 dose CR + lg o f lactoferrin,
1L2 = 1 dose CR + 2g of lactoferrin, 2L0 = 2 dose CR + Og of lactoferrin, 2L0.5 = 2 dose CR + 0.5g o f lactoferrin, 2L1 = 2dose CR +
lg o f lactoferrin, 2L2 = 2 dose CR + 2g o f lactoferrin. The largest SEM was 5.12 occurring at all time points.
* (P <0.05) Calves fed two doses o f CR had greater glucose concentrations.
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